1/293
Looks like no tags are added yet.
Autoimmunity
Conditions in which organ or tissue damage results from autoantibodies or autoreactive cells.
Self-antigens
Antigens produced by the body's own cells that may become targets of autoimmune responses.
Self-tolerance
Ability of the immune system to recognize self-antigens as non-threatening while recognizing foreign antigens as threats.
Central tolerance
Mechanism that removes or destroys self-reactive B and T lymphocytes during development.
Where does central tolerance occur?
Bone marrow and thymus.
Peripheral tolerance
Mechanism that controls self-reactive lymphocytes that escape central tolerance.
Where does peripheral tolerance occur?
Secondary lymphoid organs.
Which cells primarily mediate peripheral tolerance?
T-regulatory cells.
Main function of T-regulatory cells
Suppress immune responses against self-antigens and maintain immune balance.
Which T-helper cells are primarily associated with autoimmune disorders?
Th1 cells.
Main cause of autoimmunity
Loss or breakdown of self-tolerance.
Released sequestered antigens
Autoimmune mechanism in which normally hidden antigens become exposed to the immune system.
Molecular mimicry
Similarity between foreign and self-antigens causes cross-reactivity of immune responses.
Polyclonal B-cell activation
Activation of multiple B-cell clones, potentially promoting autoantibody production.
MHC genes and autoimmunity
Inherited MHC genes are associated with susceptibility to certain autoimmune diseases.
Two classifications of autoimmune diseases
Organ-specific and systemic.
Organ-specific autoimmune disease
Autoimmune disease directed primarily against a particular organ or tissue.
Systemic autoimmune disease
Autoimmune disease affecting multiple organs or tissues.
Hashimoto's thyroiditis
Thyroid.
Graves' disease
Thyroid.
Pernicious anemia
Gastric parietal cells.
Addison's disease
Adrenal glands.
Type I diabetes mellitus
Pancreatic beta cells.
Myasthenia gravis
Nerve-muscle synapses.
Multiple sclerosis
Myelin sheath of nerves.
Autoimmune hemolytic anemia
Red blood cells.
Idiopathic thrombocytopenic purpura
Platelets.
Goodpasture's syndrome
Kidneys and lungs.
Rheumatoid arthritis
Joints, lungs, and skin.
Scleroderma
Skin, gut, lungs, and kidneys.
Systemic lupus erythematosus
Skin, joints, kidneys, brain, heart, and lungs.
Most systemic autoimmune disease in the lecture
Systemic lupus erythematosus.
Typical peak age of SLE onset
20–40 years.
Female-to-male susceptibility ratio in SLE
Approximately 10:1.
HLA associations of SLE
HLA-DR2 and HLA-DR3.
Complement deficiencies associated with SLE
C1q, C2, and C4.
Most frequently reported clinical manifestation of SLE
Joint involvement: polyarthralgia or arthritis.
Percentage of SLE patients with joint involvement
Over 90%.
Second most common clinical manifestation of SLE
Skin manifestations.
Classic butterfly rash in SLE
Erythematous rash across the nose and cheeks.
Percentage of SLE patients with butterfly rash
Approximately 30–40%.
UV exposure and SLE
May cause erythematous rashes on exposed areas of the body.
Renal complication of SLE
Glomerulonephritis.
LE cell
Neutrophil that has engulfed the antibody-coated nucleus of another neutrophil.
Important antibody identified in SLE
Anti-DNA antibody.
SLE immunologic abnormality
Uncontrolled autoreactivity of T and B cells leading to autoantibody production.
Possible cause of uncontrolled autoreactivity in SLE
Deficiency of regulatory T cells.
Most common screening test for suspected SLE
Antinuclear antibody (ANA) test.
FANA
Fluorescent antinuclear antibody testing.
FANA sensitivity and positivity in SLE
Approximately 95%; highly sensitive but has low specificity.
Why can't ANA completely rule out SLE?
Approximately 5% of SLE patients may test negative.
ANA limitation
Low diagnostic specificity because other autoimmune diseases may also produce positive results.
Anti-dsDNA
Antibody against double-stranded DNA; associated with SLE.
Anti-dsDNA immunofluorescence pattern
Homogeneous.
Anti-ssDNA
Antibody against single-stranded DNA; associated with SLE and other diseases.
Anti-histone
Antibody against different classes of histones; associated with drug-induced SLE.
Anti-histone immunofluorescence pattern
Homogeneous.
Anti-DNP
Antibody against DNA-histone complex; associated with SLE and drug-induced SLE.
Anti-DNP immunofluorescence pattern
Homogeneous.
Anti-Sm
Antibody against an extractable nuclear antigen containing an RNA component; diagnostic for SLE.
Anti-Sm immunofluorescence pattern
Speckled.
Anti-RNP
Antibody against proteins complexed with nuclear RNA; associated with SLE and mixed connective tissue disease.
Anti-RNP immunofluorescence pattern
Speckled.
Anti-SS-A (Ro)
Antibody against proteins complexed to RNA; associated with SLE and Sjögren's syndrome.
Anti-SS-B (La)
Antibody against phosphoprotein complexed to RNA polymerase; associated with SLE and Sjögren's syndrome.
Anti-SS-A and Anti-SS-B immunofluorescence pattern
Finely speckled.
Anti-nucleolar
Antibody against RNA polymerase and nucleolar proteins.
Anti-nucleolar immunofluorescence pattern
Homogeneous staining of the nucleolus.
Anti-Scl-70
Antibody against DNA topoisomerase I; associated with systemic sclerosis and scleroderma.
Anti-Scl-70 immunofluorescence pattern
Atypical speckled.
Anti-Jo-1
Antibody against histidyl-tRNA synthetase; associated with polymyositis.
Anti-Jo-1 immunofluorescence pattern
Fine cytoplasmic speckling.
Three common FANA patterns
Homogeneous, speckled, and nucleolar.
Antiphospholipid antibodies
Heterogeneous antibodies that bind phospholipids alone or complexed with proteins.
Percentage of lupus patients with antiphospholipid antibodies
Up to 60%.
Lupus anticoagulant
One of the several types of antiphospholipid antibodies.
Coagulation tests prolonged by lupus anticoagulant
APTT and PT, according to the lecture.
Clinical concern associated with antiphospholipid antibodies
Thrombosis and increased risk of spontaneous abortion.
Female-to-male ratio in RA
Approximately 3:1.
Typical age range of RA
35–50 years.
Organs commonly affected by RA
Joints, heart, and lungs.
HLA association of RA
HLA-DR4.
Earliest immunologic finding in rheumatoid joints
Increased synovial lining cells and infiltration of mononuclear cells, mostly CD4+ T lymphocytes.
Pannus
Organized mass of inflammatory cells that grows into the joint space and invades cartilage.
Cells contributing to pannus formation
Macrophages and neutrophils, along with infiltrating immune cells.
Pro-inflammatory cytokines in RA
IL-1, IL-6, IL-8, TNF-alpha, IL-15, and IL-18.
Rheumatoid factor (RF)
Autoantibody found in approximately 75% of RA patients.
Most common immunoglobulin class of rheumatoid factor
IgM.
Target of rheumatoid factor
Fc portion of IgG.
Immune complex in RA
IgM rheumatoid factor combines with IgG.
Hypersensitivity reaction associated with RA immune complexes
Type III hypersensitivity.